Azeemuddin S K, Vega R A, Kim T H, Ragab A H
Cancer. 1987 Jun 1;59(11):1966-8. doi: 10.1002/1097-0142(19870601)59:11<1966::aid-cncr2820591122>3.0.co;2-0.
Naproxen was used as an antipyretic agent in febrile pediatric cancer patients with evidence of active malignant disease. Sixteen children with leukemia and lymphoma who had fever for more than 72 hours were given naproxen to control fever. Their ages ranged from 16 months to 17 years. There were ten female and six male patients. Their temperature was greater than 38.3 degrees C and the leukocyte count ranged from 400/microliters to 33.3 X 10(3)/microliters, with an absolute neutrophil count (ANC) from 0 to 4514/microliters. The children had no evidence of infection by clinical or laboratory evaluations. All patients were receiving triple antibiotics when naproxen was started. Fourteen patients responded to naproxen with complete lysis of fever within 6 hours of initiation of treatment. Two patients did not respond to naproxen, but proved to have culture-positive infections. There were no side effects from the drug. Naproxen is an effective antipyretic in patients with cancer. It may be useful as a means of differentiating fever secondary to active malignant disease from that due to infection.
萘普生被用作患有活动性恶性疾病证据的发热儿科癌症患者的退热剂。16名患有白血病和淋巴瘤且发热超过72小时的儿童接受了萘普生以控制发热。他们的年龄从16个月到17岁不等。有10名女性和6名男性患者。他们的体温高于38.3摄氏度，白细胞计数范围为400/微升 至33.3×10³/微升，绝对中性粒细胞计数（ANC）为0至4514/微升。通过临床或实验室评估，这些儿童没有感染的证据。开始使用萘普生时，所有患者都在接受三联抗生素治疗。14名患者在开始治疗后6小时内对萘普生有反应，发热完全消退。2名患者对萘普生无反应，但被证明有培养阳性感染。该药物没有副作用。萘普生对癌症患者是一种有效的退热剂。它可能有助于区分由活动性恶性疾病继发的发热与由感染引起的发热。
